Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: IMO, re-validated 148, is a catch all for the other 6 MMP patents and the 7 new

Thank you for the insight/opinions.

As for the "cautious" approach you suggest, I see little need for it. If we license/settle, it's a done deal and the licensee has no recourse/remedy if something arises at a later date. That is unless they negotiate a contingency clause, but I would think that would only potentially influence any additional monies (though IMO infringement is infringement, whether they infringe one patent/claim or a thousand, so "additional monies", IMO, wouldn't be in play). There's also the possible exception of ongoing royalties, which if there were a hickup downstream, they'd just stop paying. Interestingly, after a '148 recert, if there's a perception by licensees that there may be the slightest possibility of a hickup like you suggest ('336 influence on '148 - though it'd have to impact all claims, which I don't think is possible), potential licensees might feel encouraged to go the ongoing royalty route, seeing it as their only possible "out".

JMHO FWIW,

SGE

Share
New Message
Please login to post a reply